INNOVATION PHARMACEUTICAL - IPIX STOCK NEWS

Innovation Pharmaceuticals (OTCQB:IPIX) has announced a full data analysis of its Phase 2 Brilacidin COVID-19 clinical trial results, aiming for potential inclusion in larger government-sponsored trials. New in vitro data indicates Brilacidin's effectiveness as a dual-acting broad-spectrum inhibitor of coronaviruses. The study suggests that Brilacidin targets both viral and host factors, which may reduce resistance development. The Company possesses sufficient drug supply to continue clinical testing and aims to identify promising data to support future trials.

Innovation Pharmaceuticals (OTCQB:IPIX) announced topline results from its Phase 2 clinical trial of Brilacidin for treating moderate-to-severe COVID-19. The trial's primary endpoint, Time to Sustained Recovery through Day 29, showed no significant difference compared to placebo. Although the results were disappointing, the company noted the challenges of treating this patient population. Despite this, Brilacidin was well-tolerated with a lower than typical mortality rate (6.67%). Ongoing collaborations aim to explore Brilacidin's broader antiviral potential.

Innovation Pharmaceuticals (OTCQB:IPIX) announced the completion of the database lock for its Phase 2 clinical trial of Brilacidin aimed at treating moderate-to-severe COVID-19 in hospitalized patients. Statistical analysis is currently in progress, with topline results expected to be released during the week of November 8, 2021.

This milestone is crucial as it marks a significant step forward in the clinical evaluation of Brilacidin, which may provide new therapeutic options for COVID-19 patients.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that it expects to report topline results from its Phase 2 clinical trial of Brilacidin for treating moderate-to-severe COVID-19 in hospitalized patients the week of November 8th. The data is currently blinded, with final checks underway.

Additionally, Brilacidin has been shipped for in vitro testing against over 20 infectious viruses, including Ebola and Zika, through a collaboration with U.S. government scientists. The aim is to explore Brilacidin's antiviral properties further.

Innovation Pharmaceuticals (OTCQB:IPIX) provided an update on its Phase 2 clinical trial of Brilacidin for moderate-to-severe COVID-19. Study results are expected by mid-to-late October. The company has also responded to individual patient requests for Expanded Access to Brilacidin for critically ill COVID-19 patients. Preliminary research indicates Brilacidin's efficacy against various viruses including adenoviruses. The drug, with FDA Fast Track designation, aims to meet the urgent need for effective COVID-19 treatments.

Innovation Pharmaceuticals (OTCQB:IPIX) announced updates on its Phase 2 clinical trial of Brilacidin for moderate-to-severe COVID-19 treatment. Enrollment of 120 patients was completed by June 2021, with the last follow-up on July 30, 2021. Data verification is ongoing, and the company expects to disclose topline results one week post-database lock. Brilacidin, a non-peptidic drug, has shown in vitro effectiveness against SARS-CoV-2 and other viruses, positioning it for potential broad-spectrum antiviral applications.

Innovation Pharmaceuticals (OTCQB:IPIX) has provided updates on its antiviral research regarding Brilacidin, a drug candidate for COVID-19 treatment, which holds FDA Fast Track designation. The U.S. Department of Defense has canceled the Military Health System Research Symposium amid rising COVID-19 cases. Notably, Brilacidin's research manuscript detailing its ability to block SARS-CoV-2 entry into cells is under peer review. The company plans further testing against the Delta variant and other coronaviruses, reinforcing Brilacidin's potential as a broad-spectrum antiviral amidst ongoing pandemic challenges.

Innovation Pharmaceuticals (OTCQB:IPIX) announced on July 22, 2021, new data showing Brilacidin's antiviral potential against multiple human cell lines and various viral strains, including SARS-CoV-2. Presented at the American Society of Virology's annual meeting, the results suggest Brilacidin effectively inhibits viruses by disrupting viral integrity and blocking entry. Currently in clinical trials for COVID-19, Brilacidin has received U.S. FDA Fast Track designation, positioning it as a potential broad-spectrum antiviral amidst rising global demand, with the antiviral market projected to reach $44 billion by 2026.

Innovation Pharmaceuticals (OTCQB:IPIX) announced that its antiviral research on Brilacidin has been accepted for an Oral Presentation at the Military Health System Research Symposium (MHSRS) from August 23-26, 2021. Brilacidin is under clinical trial as a treatment for SARS-CoV-2 and has exhibited broad-spectrum antiviral properties. The market for antiviral drugs is projected to reach $44 billion by 2026. The presentation will focus on new data supporting its use against endemic viral diseases and the efficacy of Brilacidin in inhibiting various viruses.